Trial · NCT03205345
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
NCT03205345, Phase 2, Unknown, Conatus Pharmaceuticals Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis. Trials, record NCT03205345. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03205345
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
- NCT number
- NCT03205345
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 210 participants, estimated
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Conditions
- Decompensated Cirrhosis
- Interventions
- Emricasan (25 mg), Emricasan (5 mg), Placebo
- First posted
- 2017-07-02
- Last updated
- 2019-03-19
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Comparison of the effect of emricasan on improving event-free survival relative to placebo, based on a composite clinical endpoint | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | |
| Secondary | Improvement in MELD score | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | The effect of emricasan on improving MELD score relative to placebo |
| Secondary | Improvement in Child-Pugh scores | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | The effect of emricasan on improving the Child-Pugh score relative to placebo |
| Secondary | Reduction of the proportion of subjects with MELD score progression | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | The effect of emricasan on reducing the proportion of patients with MELD score progression (≥4 point increase at any study visit) relative to placebo |
| Secondary | Decrease in new decompensation events | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | The effect of emricasan on decreasing new decompensation events relative to placebo |
| Secondary | Decrease in liver transplantation rates | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | The effect of emricasan on decreasing liver transplantation rates (in association with MELD score ≥25) relative to placebo |
| Secondary | Decrease in all-cause and liver specific mortality | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | The effect of emricasan on decreasing all-cause and liver specific mortality relative to placebo |
| Secondary | Improvement in health-related quality of life (QOL) as measured by Short Form-36 | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) | |
| Secondary | Improvement in liver metabolic function as measured by Methacetin Breath Test (MBT) | Baseline - Final Treatment Visit (at least 48 weeks to a max of 120 weeks) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33038432 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03205345
GET https://conductscience.org/api/trials/v1/NCT03205345/registered